Overexpression of MicroRNA-133a Inhibits Ischemia-reperfusion-induced Cardiomyocyte Apoptosis by Targeting DAPK2

Overview

Journal J Hum Genet

Specialty Genetics

Date 2015 Sep 4

PMID 26334104

Citations 21

Authors

Sheng Li

Fang-Yi Xiao

Pei-Ren Shan

Lan Su

De-Liang Chen

Jin-Ye Ding

Zhi-Quan Wang

Affiliations

Soon will be listed here.

Abstract

To examine microRNA-133a (miR-133a) endogenous expression in cardiomyocytes after ischemia-reperfusion (I/R) injury and study the effects of miR-133a overexpression on I/R injury-induced cardiomyocyte apoptosis. Dual-Luciferase Reporter Assay detected dynamic expression of miR-133a. In an in vitro hypoxia-reoxygenation (HR) injury model and an in vivo rat model of I/R injury, rat cardiomyocytes were transfected with miR-133a mimic to test the effects of miR-133a overexpression on apoptosis. MiR-133a and Death Associated Protein Kinase 2 (DAPK2) mRNA expression was measured using real-time-PCR, and DAPK2 protein expression was detected by western blotting. Annexin V-fluorescein isothiocyanate/propidium iodide (PI) double-staining measured the apoptosis rate in H9C2 cells and transferase dUTP nick end labeling assay quantified the cardiomyocyte apoptosis rate in tissues obtained from in vivo the rat model. DAPK2 is a target of miR-133a. Both in vitro and in vivo results confirmed that after expression of miR-133a mimics, miR-133a levels increased, which was accompanied by decrease in DAPK2 mRNA and protein expression. In H9C2 cells, HR injury caused a sharp decrease in miR-133a expression and a significant upregualtion of DAPK2 mRNA and protein levels. However, exogenous miR-133a expression led to a significant reduction in DAPK2 mRNA and protein levels despite HR injury. Similar results were obtained from in vivo I/R injury model. After HR injury or I/R injury the apoptosis rate of myocardial cells was highly elevated and decreased significantly only after transfection of miR-133a into cardiomyocytes. MiR-133a overexpression may inhibit I/R injury-mediated cardiomyocyte apoptosis by targeting DAPK2, leading to reduced DAPK2 protein, thus miR-133a may potentially have a high therapeutic value in I/R injury.

Citing Articles

Emerging Gene Therapy Based on Nanocarriers: A Promising Therapeutic Alternative for Cardiovascular Diseases and a Novel Strategy in Valvular Heart Disease.

Yang H, Li J, Song C, Li H, Luo Q, Chen M Int J Mol Sci. 2025; 26(4).

PMID: 40004206 PMC: 11855571. DOI: 10.3390/ijms26041743.

The role of DAPK2 as a key regulatory element in various human cancers: a systematic review.

Saberiyan M, Zarei M, Safi A, Movahhed P, Khorasanian R, Adelian S Mol Biol Rep. 2024; 51(1):886.

PMID: 39105958 DOI: 10.1007/s11033-024-09761-6.

Non-Coding Ribonucleic Acids as Diagnostic and Therapeutic Targets in Cardiac Fibrosis.

Olson S, Tang W, Liu C Curr Heart Fail Rep. 2024; 21(3):262-275.

PMID: 38485860 PMC: 11090942. DOI: 10.1007/s11897-024-00653-1.

Mechanism of Qili Qiangxin Capsule for Heart Failure Based on miR133a-Endoplasmic Reticulum Stress.

Ji X, Yang D, Cui X, Lou L, Nie B, Zhao J Chin J Integr Med. 2024; 30(5):398-407.

PMID: 38386253 DOI: 10.1007/s11655-024-3654-3.

Therapeutic potentials of stem cell-derived exosomes in cardiovascular diseases.

Mani S, Gurusamy N, Ulaganathan T, Paluck A, Ramalingam S, Rajasingh J Exp Biol Med (Maywood). 2023; 248(5):434-444.

PMID: 36740769 PMC: 10281619. DOI: 10.1177/15353702231151960.

References

Tatsuguchi M, Seok H, Callis T, Thomson J, Chen J, Newman M . Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol. 2007; 42(6):1137-41. PMC: 1934409. DOI: 10.1016/j.yjmcc.2007.04.004. View

Dong D, Chen C, Huo R, Wang N, Li Z, Tu Y . Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy. Hypertension. 2010; 55(4):946-52. DOI: 10.1161/HYPERTENSIONAHA.109.139519. View

Canty Jr J, Suzuki G . Myocardial perfusion and contraction in acute ischemia and chronic ischemic heart disease. J Mol Cell Cardiol. 2011; 52(4):822-31. PMC: 3251640. DOI: 10.1016/j.yjmcc.2011.08.019. View

Ye Y, Perez-Polo J, Qian J, Birnbaum Y . The role of microRNA in modulating myocardial ischemia-reperfusion injury. Physiol Genomics. 2010; 43(10):534-42. DOI: 10.1152/physiolgenomics.00130.2010. View

Frank A, Bonney M, Bonney S, Weitzel L, Koeppen M, Eckle T . Myocardial ischemia reperfusion injury: from basic science to clinical bedside. Semin Cardiothorac Vasc Anesth. 2012; 16(3):123-32. PMC: 3457795. DOI: 10.1177/1089253211436350. View

Ivey K, Muth A, Arnold J, King F, Yeh R, Fish J . MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. Cell Stem Cell. 2008; 2(3):219-29. PMC: 2293325. DOI: 10.1016/j.stem.2008.01.016. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Luo X, Lin H, Pan Z, Xiao J, Zhang Y, Lu Y . Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. J Biol Chem. 2008; 283(29):20045-52. DOI: 10.1074/jbc.M801035200. View

Izarra A, Moscoso I, Levent E, Canon S, Cerrada I, Diez-Juan A . miR-133a enhances the protective capacity of cardiac progenitors cells after myocardial infarction. Stem Cell Reports. 2014; 3(6):1029-42. PMC: 4264058. DOI: 10.1016/j.stemcr.2014.10.010. View

10.

Townley-Tilson W, Callis T, Wang D . MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. Int J Biochem Cell Biol. 2010; 42(8):1252-5. PMC: 2904322. DOI: 10.1016/j.biocel.2009.03.002. View

11.

Siddall H, Yellon D, Ong S, Mukherjee U, Burke N, Hall A . Loss of PINK1 increases the heart's vulnerability to ischemia-reperfusion injury. PLoS One. 2013; 8(4):e62400. PMC: 3639249. DOI: 10.1371/journal.pone.0062400. View

12.

Dongworth R, Mukherjee U, Hall A, Astin R, Ong S, Yao Z . DJ-1 protects against cell death following acute cardiac ischemia-reperfusion injury. Cell Death Dis. 2014; 5:e1082. PMC: 3944257. DOI: 10.1038/cddis.2014.41. View

13.

Duisters R, Tijsen A, Schroen B, Leenders J, Lentink V, van der Made I . miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res. 2008; 104(2):170-8, 6p following 178. DOI: 10.1161/CIRCRESAHA.108.182535. View

14.

Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M . Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet. 2011; 4(4):446-54. DOI: 10.1161/CIRCGENETICS.110.958975. View

15.

Liu N, Bezprozvannaya S, Williams A, Qi X, Richardson J, Bassel-Duby R . microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 2008; 22(23):3242-54. PMC: 2600761. DOI: 10.1101/gad.1738708. View

16.

. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci. 2011; 124(Pt 18):3187. DOI: 10.1242/jcs.098830. View

17.

Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H . The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci. 2007; 120(Pt 17):3045-52. DOI: 10.1242/jcs.010728. View

18.

Tutar L, Tutar E, Tutar Y . MicroRNAs and cancer; an overview. Curr Pharm Biotechnol. 2014; 15(5):430-7. DOI: 10.2174/1389201015666140519095304. View

19.

Mathers C, Loncar D . Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3(11):e442. PMC: 1664601. DOI: 10.1371/journal.pmed.0030442. View

20.

Lin Y, Hupp T, Stevens C . Death-associated protein kinase (DAPK) and signal transduction: additional roles beyond cell death. FEBS J. 2009; 277(1):48-57. DOI: 10.1111/j.1742-4658.2009.07411.x. View